<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39412611</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1936-0541</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Hepatology international</Title><ISOAbbreviation>Hepatol Int</ISOAbbreviation></Journal><ArticleTitle>Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12072-024-10731-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The international consensus to revise non-alcoholic fatty liver disease to metabolic (dysfunction)-associated fatty liver disease (MAFLD) in 2020 attracted significant attention. The impact of the MAFLD definition on the research community has not been objectively assessed. We conducted an analysis of systematically collected literature on MAFLD to understand its research impact.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From PubMed, Web of Science, and Scopus, the literature adopting MAFLD, written in English, and published from 2020 to 10 October 2023 was collected. The publication metrics, including publication counts, publishing journals, author countries, author keywords, and citation information, were analyzed to evaluate the research impact and key topics on MAFLD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">1469 MAFLD-related papers were published in 434 journals with a steady increase in the number. The intense publishing and citations activity on MAFLD indicates the large impact of the redefinition. Topic assessment with keyword and citation analysis revealed a transition from the proposal and discussion of the redefinition to clinical characterization of MAFLD with a focus on metabolic dysfunction. Moreover, the diagnostic criteria for MAFLD showed better performance in predicting hepatic and extrahepatic outcomes compared to NAFLD. The publications were from 99 countries with evidence of strong regional and global collaboration. Multiple international societies and stakeholders have endorsed MAFLD for its utility in clinical practice, improving patient management and promoting multidisciplinary care, while alleviating stigma.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This survey provides a quantitative measure of the considerable international impact and contributions of the MAFLD definition towards liver research and as part of the spectrum of cardiometabolic disorders.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Suoh</LastName><ForeName>Maito</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Storr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, 176 Hawkesbury Rd, Westmead, NSW, 2145, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esmaili</LastName><ForeName>Saeed</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Storr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, 176 Hawkesbury Rd, Westmead, NSW, 2145, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eslam</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Storr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, 176 Hawkesbury Rd, Westmead, NSW, 2145, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>George</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8421-5476</Identifier><AffiliationInfo><Affiliation>Storr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, 176 Hawkesbury Rd, Westmead, NSW, 2145, Australia. jacob.george@sydney.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>APP1053206</GrantID><Agency>National Health and Medical Research Council of Australia</Agency><Country /></Grant><Grant><GrantID>APP2001692</GrantID><Agency>National Health and Medical Research Council of Australia</Agency><Country /></Grant><Grant><GrantID>APP1107178</GrantID><Agency>National Health and Medical Research Council of Australia</Agency><Country /></Grant><Grant><GrantID>APP1108422</GrantID><Agency>National Health and Medical Research Council of Australia</Agency><Country /></Grant><Grant><GrantID>APP1196492</GrantID><Agency>National Health and Medical Research Council of Australia</Agency><Country /></Grant><Grant><GrantID>2021/ATRG2028</GrantID><Agency>Cancer Institute NSW</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hepatol Int</MedlineTA><NlmUniqueID>101304009</NlmUniqueID><ISSNLinking>1936-0533</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bibliographic network</Keyword><Keyword MajorTopicYN="N">Bibliometric analysis</Keyword><Keyword MajorTopicYN="N">Bibliometrics</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cardiovascular disease</Keyword><Keyword MajorTopicYN="N">Chronic kidney disease</Keyword><Keyword MajorTopicYN="N">Co-citation network</Keyword><Keyword MajorTopicYN="N">Co-occurrence network</Keyword><Keyword MajorTopicYN="N">Liver fibrosis</Keyword><Keyword MajorTopicYN="N">MAFLD</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>11</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39412611</ArticleId><ArticleId IdType="doi">10.1007/s12072-024-10731-0</ArticleId><ArticleId IdType="pii">10.1007/s12072-024-10731-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eslam M, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889–919</Citation><ArticleIdList><ArticleId IdType="pubmed">33006093</ArticleId><ArticleId IdType="doi">10.1007/s12072-020-10094-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Eslam M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209</Citation><ArticleIdList><ArticleId IdType="pubmed">32278004</ArticleId><ArticleId IdType="doi">10.1016/j.jhep.2020.03.039</ArticleId></ArticleIdList></Reference><Reference><Citation>Eslam M, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014</Citation><ArticleIdList><ArticleId IdType="pubmed">32044314</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2019.11.312</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou XD, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023;17(4):773–791</Citation><ArticleIdList><ArticleId IdType="pubmed">37204656</ArticleId><ArticleId IdType="doi">10.1007/s12072-023-10543-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun DQ, et al. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease. Hepatobiliary Surg Nutr. 2023;12(3):386–403</Citation><ArticleIdList><ArticleId IdType="pubmed">37351121</ArticleId><ArticleId IdType="pmc">10282675</ArticleId><ArticleId IdType="doi">10.21037/hbsn-22-421</ArticleId></ArticleIdList></Reference><Reference><Citation>Fouad Y, et al. What’s in a name? Renaming “NAFLD” to “MAFLD.” Liver Int. 2020;40(6):1254–1261</Citation><ArticleIdList><ArticleId IdType="pubmed">32301554</ArticleId><ArticleId IdType="doi">10.1111/liv.14478</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilg H, et al. From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol. 2020;17(7):387–388</Citation><ArticleIdList><ArticleId IdType="pubmed">32461575</ArticleId><ArticleId IdType="doi">10.1038/s41575-020-0316-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiha G, et al. Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol. 2021;6(1):73–79</Citation><ArticleIdList><ArticleId IdType="pubmed">33031758</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(20)30294-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Younossi ZM, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology. 2021;73(3):1194–1198</Citation><ArticleIdList><ArticleId IdType="pubmed">32544255</ArticleId><ArticleId IdType="doi">10.1002/hep.31420</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiha G, et al. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. Lancet Gastroenterol Hepatol. 2021;6(1):57–64</Citation><ArticleIdList><ArticleId IdType="pubmed">33181119</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(20)30213-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez-Sanchez N, et al. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol. 2021;6(1):65–72</Citation><ArticleIdList><ArticleId IdType="pubmed">33181118</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(20)30340-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Nan Y, et al. The Chinese society of hepatology position statement on the redefinition of fatty liver disease. J Hepatol. 2021;75(2):454–461</Citation><ArticleIdList><ArticleId IdType="pubmed">34019941</ArticleId><ArticleId IdType="doi">10.1016/j.jhep.2021.05.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez-Sanchez N, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7(5):388–390</Citation><ArticleIdList><ArticleId IdType="pubmed">35248211</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(22)00062-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Alharthi J, et al. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol. 2022;38(3):251–260</Citation><ArticleIdList><ArticleId IdType="pubmed">35143431</ArticleId><ArticleId IdType="doi">10.1097/MOG.0000000000000823</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamid S, et al. WGO guidance for the care of patients with COVID-19 and liver disease. J Clin Gastroenterol. 2021;55(1):1–11</Citation><ArticleIdList><ArticleId IdType="pubmed">33230011</ArticleId><ArticleId IdType="doi">10.1097/MCG.0000000000001459</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefan N, et al. Global pandemics interconnected - obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol. 2021;17(3):135–149</Citation><ArticleIdList><ArticleId IdType="pubmed">33479538</ArticleId><ArticleId IdType="doi">10.1038/s41574-020-00462-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinella ME, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986</Citation><ArticleIdList><ArticleId IdType="pubmed">37363821</ArticleId></ArticleIdList></Reference><Reference><Citation>Donthu N, et al. How to conduct a bibliometric analysis: An overview and guidelines. J Bus Res. 2021;133:285–296</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbusres.2021.04.070</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang TS, et al. Global publication trends and research hotspots of nonalcoholic fatty liver disease: a bibliometric analysis and systematic review. Springerplus. 2015;4:776</Citation><ArticleIdList><ArticleId IdType="pubmed">26697286</ArticleId><ArticleId IdType="pmc">4678134</ArticleId><ArticleId IdType="doi">10.1186/s40064-015-1542-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. Emerging trends and hotspots in the links between the gut microbiota and MAFLD from 2002 to 2021: a bibliometric analysis. Front Endocrinol. 2022;13: 990953</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.990953</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, et al. Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: a bibliometric analysis. Front Endocrinol. 2023;14:1078149</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2023.1078149</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo K, et al. Study on inflammation and fibrogenesis in MAFLD from 2000 to 2022: a bibliometric analysis. Front Endocrinol (Lausanne). 2023;14:1231520</Citation><ArticleIdList><ArticleId IdType="pubmed">37720529</ArticleId><ArticleId IdType="doi">10.3389/fendo.2023.1231520</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai JJ, et al. Global trends and hotspots of treatment for nonalcoholic fatty liver disease: a bibliometric and visualization analysis (2010–2023). World J Gastroenterol. 2023;29(37):5339–5360</Citation><ArticleIdList><ArticleId IdType="pubmed">37899789</ArticleId><ArticleId IdType="pmc">10600806</ArticleId><ArticleId IdType="doi">10.3748/wjg.v29.i37.5339</ArticleId></ArticleIdList></Reference><Reference><Citation>Aria M, et al. bibliometrix : an R-tool for comprehensive science mapping analysis. J Informet. 2017;11(4):959–975</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joi.2017.08.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Waltman L. A review of the literature on citation impact indicators. J Inform. 2016;10(2):365–391</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joi.2016.02.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Perianes-Rodriguez A, et al. Constructing bibliometric networks: a comparison between full and fractional counting. J Inform. 2016;10(4):1178–1195</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joi.2016.10.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Opsahl T, et al. Node centrality in weighted networks: Generalizing degree and shortest paths. Soc Netw. 2010;32(3):245–251</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socnet.2010.03.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Traag VA, et al. From Louvain to Leiden: guaranteeing well-connected communities. Sci Rep. 2019;9(1):5233</Citation><ArticleIdList><ArticleId IdType="pubmed">30914743</ArticleId><ArticleId IdType="pmc">6435756</ArticleId><ArticleId IdType="doi">10.1038/s41598-019-41695-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu W, et al. Liver fibrosis and MAFLD: from molecular aspects to novel pharmacological strategies. Front Med. 2021;8: 761538</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.761538</ArticleId></ArticleIdList></Reference><Reference><Citation>Xian YX, et al. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J. 2020;134(1):8–19</Citation><ArticleIdList><ArticleId IdType="pubmed">33323806</ArticleId><ArticleId IdType="pmc">7862804</ArticleId><ArticleId IdType="doi">10.1097/CM9.0000000000001263</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchay MS, et al. Pathophysiological mechanisms underlying MAFLD. Diabetes Metab Syndr. 2020;14(6):1875–1887</Citation><ArticleIdList><ArticleId IdType="pubmed">32998095</ArticleId><ArticleId IdType="doi">10.1016/j.dsx.2020.09.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim S, et al. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2021;32(7):500–514</Citation><ArticleIdList><ArticleId IdType="pubmed">33975804</ArticleId><ArticleId IdType="doi">10.1016/j.tem.2021.04.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40(9):2082–2089</Citation><ArticleIdList><ArticleId IdType="pubmed">32478487</ArticleId><ArticleId IdType="doi">10.1111/liv.14548</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng KI, et al. Letter to the editor: obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020;108: 154244</Citation><ArticleIdList><ArticleId IdType="pubmed">32320741</ArticleId><ArticleId IdType="pmc">7166301</ArticleId><ArticleId IdType="doi">10.1016/j.metabol.2020.154244</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamura S, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;40(12):3018–3030</Citation><ArticleIdList><ArticleId IdType="pubmed">32997882</ArticleId><ArticleId IdType="doi">10.1111/liv.14675</ArticleId></ArticleIdList></Reference><Reference><Citation>Remmerie A, et al. Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the fatty liver. Immunity. 2020;53(3):641–657</Citation><ArticleIdList><ArticleId IdType="pubmed">32888418</ArticleId><ArticleId IdType="pmc">7501731</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2020.08.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, et al. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide Cohort Study. Clin Gastroenterol Hepatol. 2021;19(10):2138–2147</Citation><ArticleIdList><ArticleId IdType="pubmed">33348045</ArticleId><ArticleId IdType="doi">10.1016/j.cgh.2020.12.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021;75(6):1284–1291</Citation><ArticleIdList><ArticleId IdType="pubmed">34380057</ArticleId><ArticleId IdType="doi">10.1016/j.jhep.2021.07.035</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun DQ, et al. MAFLD and risk of CKD. Metabolism. 2021;115: 154433</Citation><ArticleIdList><ArticleId IdType="pubmed">33212070</ArticleId><ArticleId IdType="doi">10.1016/j.metabol.2020.154433</ArticleId></ArticleIdList></Reference><Reference><Citation>Targher G, et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020;69(8):1545–1547</Citation><ArticleIdList><ArticleId IdType="pubmed">32414813</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2020-321611</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong VW, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol. 2021;19(10):2161–2171</Citation><ArticleIdList><ArticleId IdType="pubmed">33137486</ArticleId><ArticleId IdType="doi">10.1016/j.cgh.2020.10.046</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsutsumi T, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res. 2021;51(11):1115–1128</Citation><ArticleIdList><ArticleId IdType="pubmed">34129272</ArticleId><ArticleId IdType="doi">10.1111/hepr.13685</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen VH, et al. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. Clin Gastroenterol Hepatol. 2021;19(10):2172–2181</Citation><ArticleIdList><ArticleId IdType="pubmed">34033923</ArticleId><ArticleId IdType="doi">10.1016/j.cgh.2021.05.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Niriella MA, et al. Outcomes of NAFLD and MAFLD: results from a community-based, prospective cohort study. PLoS ONE. 2021;16(2): e0245762</Citation><ArticleIdList><ArticleId IdType="pubmed">33534815</ArticleId><ArticleId IdType="pmc">7857550</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0245762</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Q, et al. NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality?-results from NHANES III. Front Med. 2021;8: 693507</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.693507</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro GTS, et al. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD? Hepatol Int. 2021;15(2):380–391</Citation><ArticleIdList><ArticleId IdType="pubmed">33694066</ArticleId><ArticleId IdType="doi">10.1007/s12072-021-10157-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim GEH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2023;21(3):619–629</Citation><ArticleIdList><ArticleId IdType="pubmed">34871813</ArticleId><ArticleId IdType="doi">10.1016/j.cgh.2021.11.038</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kleef LA, et al. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: the Rotterdam Study. Hepatology. 2022;75(2):419–429</Citation><ArticleIdList><ArticleId IdType="pubmed">34453359</ArticleId><ArticleId IdType="doi">10.1002/hep.32131</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y, et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year Cohort study in China. J Clin Endocrinol Metab. 2022;107(1):88–97</Citation><ArticleIdList><ArticleId IdType="pubmed">34508601</ArticleId><ArticleId IdType="doi">10.1210/clinem/dgab641</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KE, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691–2700</Citation><ArticleIdList><ArticleId IdType="pubmed">35587339</ArticleId><ArticleId IdType="doi">10.1210/clinem/dgac321</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol. 2022;20(3):e573–e582</Citation><ArticleIdList><ArticleId IdType="pubmed">33618024</ArticleId><ArticleId IdType="doi">10.1016/j.cgh.2021.02.030</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YL, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol. 2021;21(1):212</Citation><ArticleIdList><ArticleId IdType="pubmed">33971822</ArticleId><ArticleId IdType="pmc">8111711</ArticleId><ArticleId IdType="doi">10.1186/s12876-021-01782-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Eren F, et al. Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals. Eur J Gastroenterol Hepatol. 2022;34(1):98–103</Citation><ArticleIdList><ArticleId IdType="pubmed">32976186</ArticleId><ArticleId IdType="doi">10.1097/MEG.0000000000001946</ArticleId></ArticleIdList></Reference><Reference><Citation>Eslam M, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19(10):638–651</Citation><ArticleIdList><ArticleId IdType="pubmed">35710982</ArticleId><ArticleId IdType="doi">10.1038/s41575-022-00635-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo B, et al. Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease. J Hepatol. 2022;76(3):518–525</Citation><ArticleIdList><ArticleId IdType="pubmed">34883157</ArticleId><ArticleId IdType="doi">10.1016/j.jhep.2021.10.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YL, et al. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. World J Gastroenterol. 2021;27(34):5753–5763</Citation><ArticleIdList><ArticleId IdType="pubmed">34629799</ArticleId><ArticleId IdType="pmc">8473595</ArticleId><ArticleId IdType="doi">10.3748/wjg.v27.i34.5753</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz Y, et al. The prevalence of metabolic-associated fatty liver disease in the Turkish population: a multicenter study. Hepatol Forum. 2021;2(2):37–42</Citation><ArticleIdList><ArticleId IdType="pubmed">35783905</ArticleId><ArticleId IdType="pmc">9138918</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakurai Y, et al. Role of insulin resistance in MAFLD. Int J Mol Sci. 2021;22(8):4156</Citation><ArticleIdList><ArticleId IdType="pubmed">33923817</ArticleId><ArticleId IdType="pmc">8072900</ArticleId><ArticleId IdType="doi">10.3390/ijms22084156</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, et al. MAFLD criteria guide the subtyping of patients with fatty liver disease. Risk Manag Healthc Policy. 2021;14:491–501</Citation><ArticleIdList><ArticleId IdType="pubmed">33603515</ArticleId><ArticleId IdType="pmc">7881793</ArticleId><ArticleId IdType="doi">10.2147/RMHP.S285880</ArticleId></ArticleIdList></Reference><Reference><Citation>Heeren J, et al. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab. 2021;50: 101238</Citation><ArticleIdList><ArticleId IdType="pubmed">33892169</ArticleId><ArticleId IdType="pmc">8324684</ArticleId><ArticleId IdType="doi">10.1016/j.molmet.2021.101238</ArticleId></ArticleIdList></Reference><Reference><Citation>Flisiak-Jackiewicz M, et al. From nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD)-new terminology in pediatric patients as a step in good scientific direction? J Clin Med. 2021;10(5):924</Citation><ArticleIdList><ArticleId IdType="pubmed">33804296</ArticleId><ArticleId IdType="pmc">7957610</ArticleId><ArticleId IdType="doi">10.3390/jcm10050924</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Gorman P, et al. Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention. Aliment Pharmacol Ther. 2020;52(8):1387–1398</Citation><ArticleIdList><ArticleId IdType="pubmed">32717123</ArticleId><ArticleId IdType="doi">10.1111/apt.15989</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomar A, et al. Association of obstructive sleep apnea with nocturnal hypoxemia in metabolic-associated fatty liver disease patients: a cross-sectional analysis of record-based data. J Family Med Prim Care. 2021;10(8):3105–3110</Citation><ArticleIdList><ArticleId IdType="pubmed">34660454</ArticleId><ArticleId IdType="pmc">8483116</ArticleId><ArticleId IdType="doi">10.4103/jfmpc.jfmpc_412_21</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou YJ, et al. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: a multicenter preliminary analysis. J Hepatol. 2020;73(3):719–721</Citation><ArticleIdList><ArticleId IdType="pubmed">32348790</ArticleId><ArticleId IdType="pmc">7195041</ArticleId><ArticleId IdType="doi">10.1016/j.jhep.2020.04.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan L, et al. Metabolic associated fatty liver disease increases the severity of COVID-19: a meta-analysis. Dig Liver Dis. 2021;53(2):153–157</Citation><ArticleIdList><ArticleId IdType="pubmed">33011088</ArticleId><ArticleId IdType="doi">10.1016/j.dld.2020.09.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou YJ, et al. Metabolic-associated fatty liver disease is associated with severity of COVID-19. Liver Int. 2020;40(9):2160–2163</Citation><ArticleIdList><ArticleId IdType="pubmed">32573883</ArticleId><ArticleId IdType="pmc">7361853</ArticleId><ArticleId IdType="doi">10.1111/liv.14575</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao F, et al. Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. J Gastroenterol Hepatol. 2021;36(1):204–207</Citation><ArticleIdList><ArticleId IdType="pubmed">32436622</ArticleId><ArticleId IdType="doi">10.1111/jgh.15112</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegyi PJ, et al. Metabolic associated fatty liver disease is associated with an increased risk of severe COVID-19: a systematic review with meta-analysis. Front Med. 2021;8: 626425</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.626425</ArticleId></ArticleIdList></Reference><Reference><Citation>Alharthi J, et al. Macrophages in metabolic associated fatty liver disease. World J Gastroenterol. 2020;26(16):1861–1878</Citation><ArticleIdList><ArticleId IdType="pubmed">32390698</ArticleId><ArticleId IdType="pmc">7201150</ArticleId><ArticleId IdType="doi">10.3748/wjg.v26.i16.1861</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma P, et al. Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19. Diabetes Metab Syndr. 2020;14(5):825–827</Citation><ArticleIdList><ArticleId IdType="pubmed">32540736</ArticleId><ArticleId IdType="pmc">7834636</ArticleId><ArticleId IdType="doi">10.1016/j.dsx.2020.06.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao Z, et al. Risk of severe COVID-19 increased by metabolic dysfunction-associated fatty liver disease: a meta-analysis. J Clin Gastroenterol. 2021;55(10):830–835</Citation><ArticleIdList><ArticleId IdType="pubmed">34406175</ArticleId><ArticleId IdType="pmc">8500209</ArticleId><ArticleId IdType="doi">10.1097/MCG.0000000000001605</ArticleId></ArticleIdList></Reference><Reference><Citation>Farahat TM, et al. The paradigm shift from NAFLD to MAFLD: a global primary care viewpoint. Liver Int. 2022;42(6):1259–1267</Citation><ArticleIdList><ArticleId IdType="pubmed">35129258</ArticleId><ArticleId IdType="doi">10.1111/liv.15188</ArticleId></ArticleIdList></Reference><Reference><Citation>Spearman CW, et al. Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa. Lancet Gastroenterol Hepatol. 2022;7(11):1036–1048</Citation><ArticleIdList><ArticleId IdType="pubmed">35810766</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(22)00041-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Eslam M, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021;6(10):864–873</Citation><ArticleIdList><ArticleId IdType="pubmed">34364544</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(21)00183-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho SH, et al. Metabolic dysfunction-associated fatty liver disease and heavy alcohol consumption increase mortality: a nationwide study. Hepatol Int. 2024;18(4):1168–1177</Citation><ArticleIdList><ArticleId IdType="pubmed">38806774</ArticleId><ArticleId IdType="doi">10.1007/s12072-024-10671-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitale A, et al. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database. Gut. 2023;72(1):141–152</Citation><ArticleIdList><ArticleId IdType="pubmed">34933916</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2021-324915</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VL, et al. Effects of cirrhosis and diagnosis scenario in metabolic-associated fatty liver disease-related hepatocellular carcinoma. Hepatol Commun. 2021;5(1):122–132</Citation><ArticleIdList><ArticleId IdType="pubmed">33437906</ArticleId><ArticleId IdType="doi">10.1002/hep4.1606</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers S, et al. NAFLD and MAFLD as emerging causes of HCC: a populational study. JHEP Rep. 2021;3(2): 100231</Citation><ArticleIdList><ArticleId IdType="pubmed">33748726</ArticleId><ArticleId IdType="pmc">7957147</ArticleId><ArticleId IdType="doi">10.1016/j.jhepr.2021.100231</ArticleId></ArticleIdList></Reference><Reference><Citation>Song BG, et al. Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma. JHEP Rep. 2023;5(9): 100810</Citation><ArticleIdList><ArticleId IdType="pubmed">37538246</ArticleId><ArticleId IdType="pmc">10393797</ArticleId><ArticleId IdType="doi">10.1016/j.jhepr.2023.100810</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane H, et al. Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Clin Mol Hepatol. 2024;30(3):436–448</Citation><ArticleIdList><ArticleId IdType="pubmed">38623613</ArticleId><ArticleId IdType="pmc">11261220</ArticleId><ArticleId IdType="doi">10.3350/cmh.2024.0109</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T, et al. MAFLD Is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma. Clin Mol Hepatol. 2024. https://doi.org/10.3350/cmh.2024.0372</Citation><ArticleIdList><ArticleId IdType="doi">10.3350/cmh.2024.0372</ArticleId><ArticleId IdType="pubmed">38768960</ArticleId></ArticleIdList></Reference><Reference><Citation>Conci S, et al. Hepatectomy for metabolic associated fatty liver disease (MAFLD) related HCC: propensity case-matched analysis with viral- and alcohol-related HCC. Eur J Surg Oncol. 2022;48(1):103–112</Citation><ArticleIdList><ArticleId IdType="pubmed">34325939</ArticleId><ArticleId IdType="doi">10.1016/j.ejso.2021.07.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MN, et al. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients. Int J Cancer. 2023;153(8):1448–1458</Citation><ArticleIdList><ArticleId IdType="pubmed">37439276</ArticleId><ArticleId IdType="doi">10.1002/ijc.34637</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SC, et al. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B. Hepatol Int. 2023;17(5):1139–1149</Citation><ArticleIdList><ArticleId IdType="pubmed">37247045</ArticleId><ArticleId IdType="doi">10.1007/s12072-023-10545-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimose S, et al. The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma. Hepatol Res. 2023;53(2):104–115</Citation><ArticleIdList><ArticleId IdType="pubmed">36149726</ArticleId><ArticleId IdType="doi">10.1111/hepr.13843</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimini M, et al. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open. 2022;7(6): 100591</Citation><ArticleIdList><ArticleId IdType="pubmed">36208496</ArticleId><ArticleId IdType="pmc">9808460</ArticleId><ArticleId IdType="doi">10.1016/j.esmoop.2022.100591</ArticleId></ArticleIdList></Reference><Reference><Citation>Casadei-Gardini A, et al. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. Eur J Cancer. 2023;180:9–20</Citation><ArticleIdList><ArticleId IdType="pubmed">36527976</ArticleId><ArticleId IdType="doi">10.1016/j.ejca.2022.11.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Argenziano ME, et al. Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients. Hepatol Int. 2024. https://doi.org/10.1007/s12072-024-10692-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12072-024-10692-4</ArticleId><ArticleId IdType="pubmed">39012579</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YC, et al. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population. Hepatol Int. 2022;16(4):835–845</Citation><ArticleIdList><ArticleId IdType="pubmed">35701716</ArticleId><ArticleId IdType="doi">10.1007/s12072-022-10362-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Inamine S, et al. Metabolic dysfunction-associated fatty liver disease directly related to liver fibrosis independent of insulin resistance, hyperlipidemia, and alcohol intake in morbidly obese patients. Hepatol Res. 2022;52(10):841–858</Citation><ArticleIdList><ArticleId IdType="pubmed">35815420</ArticleId><ArticleId IdType="doi">10.1111/hepr.13808</ArticleId></ArticleIdList></Reference><Reference><Citation>Miwa T, et al. Impact of body fat accumulation on metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease in Japanese male young adults. Hepatol Res. 2023;53(8):691–700</Citation><ArticleIdList><ArticleId IdType="pubmed">37143429</ArticleId><ArticleId IdType="doi">10.1111/hepr.13906</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, et al. A simpler definition of MAFLD precisely predicts incident metabolic diseases: a 7-year cohort study. Hepatol Int. 2023;17(5):1182–1191</Citation><ArticleIdList><ArticleId IdType="pubmed">37322380</ArticleId><ArticleId IdType="doi">10.1007/s12072-023-10558-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu HH, et al. Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case-control study. Hepatol Int. 2021;15(6):1337–1346</Citation><ArticleIdList><ArticleId IdType="pubmed">34626331</ArticleId><ArticleId IdType="doi">10.1007/s12072-021-10252-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, et al. Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants. Hepatol Int. 2023;17(3):595–605</Citation><ArticleIdList><ArticleId IdType="pubmed">36809487</ArticleId><ArticleId IdType="doi">10.1007/s12072-023-10486-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, et al. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers. Metabolism. 2022;127: 154955</Citation><ArticleIdList><ArticleId IdType="pubmed">34915036</ArticleId><ArticleId IdType="doi">10.1016/j.metabol.2021.154955</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukunaga S, et al. Impact of non-obese metabolic dysfunction-associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: a multicenter study. Hepatol Res. 2024;54(2):201–212</Citation><ArticleIdList><ArticleId IdType="pubmed">37796562</ArticleId><ArticleId IdType="doi">10.1111/hepr.13973</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakane T, et al. Impact of metabolic dysfunction-associated fatty liver disease on the incidence of Helicobacter pylori-negative gastric cancer. Hepatol Res. 2024;54(6):540–550</Citation><ArticleIdList><ArticleId IdType="pubmed">38156966</ArticleId><ArticleId IdType="doi">10.1111/hepr.14010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, et al. Metabolic dysfunction-associated fatty liver disease increases colon cancer risk: a nationwide Cohort Study. Clin Transl Gastroenterol. 2022;13(1): e00435</Citation><ArticleIdList><ArticleId IdType="pubmed">35080508</ArticleId><ArticleId IdType="pmc">8806363</ArticleId><ArticleId IdType="doi">10.14309/ctg.0000000000000435</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YL, et al. Impact of thyroid function on the prevalence and mortality of metabolic dysfunction-associated fatty liver disease. J Clin Endocrinol Metab. 2023;108(7):e434–e443</Citation><ArticleIdList><ArticleId IdType="pubmed">36637992</ArticleId><ArticleId IdType="doi">10.1210/clinem/dgad016</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukunaga S, et al. Lean/normal-weight metabolic dysfunction-associated fatty liver disease is a risk factor for reflux esophagitis. Hepatol Res. 2022;52(8):699–711</Citation><ArticleIdList><ArticleId IdType="pubmed">35585481</ArticleId><ArticleId IdType="doi">10.1111/hepr.13795</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsutsumi T, et al. MAFLD associated with COPD via systemic inflammation independent of aging and smoking in men. Diabetol Metab Syndr. 2022;14(1):115</Citation><ArticleIdList><ArticleId IdType="pubmed">35974418</ArticleId><ArticleId IdType="pmc">9380323</ArticleId><ArticleId IdType="doi">10.1186/s13098-022-00887-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsutsumi T, et al. The inter-organ crosstalk reveals an inevitable link between MAFLD and extrahepatic diseases. Nutrients. 2023;15(5):1123</Citation><ArticleIdList><ArticleId IdType="pubmed">36904122</ArticleId><ArticleId IdType="pmc">10005526</ArticleId><ArticleId IdType="doi">10.3390/nu15051123</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawaguchi T, et al. MAFLD: renovation of clinical practice and disease awareness of fatty liver. Hepatol Res. 2022;52(5):422–432</Citation><ArticleIdList><ArticleId IdType="pubmed">34472683</ArticleId><ArticleId IdType="doi">10.1111/hepr.13706</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams LA, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138–1153</Citation><ArticleIdList><ArticleId IdType="pubmed">28314735</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2017-313884</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez-Mejia MM, et al. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification? Hepatol Int. 2024;18(1):168–178</Citation><ArticleIdList><ArticleId IdType="pubmed">38127259</ArticleId><ArticleId IdType="doi">10.1007/s12072-023-10620-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Z, et al. MAFLD identifies patients with significant hepatic fibrosis better than MASLD. Hepatol Int. 2024;18(3):964–972</Citation><ArticleIdList><ArticleId IdType="pubmed">38717690</ArticleId><ArticleId IdType="doi">10.1007/s12072-024-10673-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Z, et al. MAFLD predicts cardiovascular disease risk better than MASLD. Liver Int. 2024;44(7):1567–1574</Citation><ArticleIdList><ArticleId IdType="pubmed">38641962</ArticleId><ArticleId IdType="doi">10.1111/liv.15931</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Z, et al. MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease. Ann Hepatol. 2024;29(5): 101512</Citation><ArticleIdList><ArticleId IdType="pubmed">38710473</ArticleId><ArticleId IdType="doi">10.1016/j.aohep.2024.101512</ArticleId></ArticleIdList></Reference><Reference><Citation>Choe HJ, et al. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up. Metabolism. 2024;153: 155800</Citation><ArticleIdList><ArticleId IdType="pubmed">38266957</ArticleId><ArticleId IdType="doi">10.1016/j.metabol.2024.155800</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwak M, et al. MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: a population-based study with 26.7 years of follow-up. Hepatology. 2024. https://doi.org/10.1097/HEP.0000000000000925</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HEP.0000000000000925</ArticleId><ArticleId IdType="pubmed">38739848</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciardullo S, et al. Exploring the landscape of steatotic liver disease in the general US population. Liver Int. 2023;43(11):2425–2433</Citation><ArticleIdList><ArticleId IdType="pubmed">37592856</ArticleId><ArticleId IdType="doi">10.1111/liv.15695</ArticleId></ArticleIdList></Reference><Reference><Citation>Song R, et al. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults. Liver Int. 2024;44(4):1051–1060</Citation><ArticleIdList><ArticleId IdType="pubmed">38293788</ArticleId><ArticleId IdType="doi">10.1111/liv.15856</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, et al. Steatotic liver disease-associated all-cause/cause-specific mortality in the United States. Aliment Pharmacol Ther. 2024;60(1):33–42</Citation><ArticleIdList><ArticleId IdType="pubmed">38649335</ArticleId><ArticleId IdType="doi">10.1111/apt.18011</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang T, et al. Evaluation of nomenclature of fatty liver disease in association with hepatocellular carcinoma: a 15.5-year Cohort Study in Korea. 2024. https://doi.org/10.2139/ssrn.4879244 .</Citation></Reference><Reference><Citation>Fouad Y, et al. Letter to the editor: how F to S turned the premature to be mature? Hepatology. 2024;79(6):E157–E158</Citation><ArticleIdList><ArticleId IdType="pubmed">38150267</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez-Mejia MM, et al. The MAFLD and MASLD conundrum: Is it reinvention of the wheel? J Hepatol. 2024;81(1):e22–e23</Citation><ArticleIdList><ArticleId IdType="pubmed">38484916</ArticleId><ArticleId IdType="doi">10.1016/j.jhep.2024.03.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanal MG. Is the change from NAFLD to MASLD driven by political correctness? J Hepatol. 2024;80(2):e74–e76</Citation><ArticleIdList><ArticleId IdType="pubmed">37683734</ArticleId><ArticleId IdType="doi">10.1016/j.jhep.2023.08.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonardo A, et al. Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclature. J Hepatol. 2024;80(5):e192–e194</Citation><ArticleIdList><ArticleId IdType="pubmed">38336589</ArticleId><ArticleId IdType="doi">10.1016/j.jhep.2024.01.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Clayton M, et al. From NAFLD to MAFLD: nurse and allied health perspective. Liver Int. 2021;41(4):683–691</Citation><ArticleIdList><ArticleId IdType="pubmed">33453067</ArticleId><ArticleId IdType="doi">10.1111/liv.14788</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiha G, et al. MAFLD 2022: An ELPA/ALPA/EASO-ECPO joint statement on disease stigma. J Hepatol. 2022;77(6):1717–1719</Citation><ArticleIdList><ArticleId IdType="pubmed">36055431</ArticleId><ArticleId IdType="doi">10.1016/j.jhep.2022.08.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Younossi ZM, et al. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease. J Hepatol. 2024;80(3):419–430</Citation><ArticleIdList><ArticleId IdType="pubmed">37984709</ArticleId><ArticleId IdType="doi">10.1016/j.jhep.2023.11.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Alboraie M, et al. Letter to the Editor: MAFLD versus MASLD-Which is more appropriate from a global perspective? Hepatology. 2024. https://doi.org/10.1097/HEP.0000000000000886</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HEP.0000000000000886</ArticleId><ArticleId IdType="pubmed">38713880</ArticleId></ArticleIdList></Reference><Reference><Citation>Fouad Y, et al. Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition. J Hepatol. 2024;80(5):e194–e197</Citation><ArticleIdList><ArticleId IdType="pubmed">38342440</ArticleId><ArticleId IdType="doi">10.1016/j.jhep.2024.01.033</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao L, et al. “Fatty” or “steatotic”: position statement from a linguistic perspective by the Chinese-speaking community. J Hepatol. 2024. https://doi.org/10.1016/j.jhep.2024.05.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2024.05.031</ArticleId><ArticleId IdType="pubmed">38823502</ArticleId></ArticleIdList></Reference><Reference><Citation>Belter CW. Bibliometric indicators: opportunities and limits. J Med Libr Assoc. 2015;103(4):219–221</Citation><ArticleIdList><ArticleId IdType="pubmed">26512227</ArticleId><ArticleId IdType="pmc">4613388</ArticleId><ArticleId IdType="doi">10.3163/1536-5050.103.4.014</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>